Although encouraging results from existing vaccines, a resurgence of COVID-19 cases at least in parts of the world from Russia, Southeast Asia, and even parts of the United States, the Delta SARS-CoV-2 variant becomes a bigger concern of public health authorities. Consequently, Pfizer and BioNTech recently announced the development of a booster vaccine with an aim of launching clinical trials in August. That’s because the Delta variant appears to be 60% more contagious than the variant from the UK, for example, and possibly as much as twice the transmissibility of the original SARS-CoV-2. With big swathes of America not heavily vaccinated, the fear is that new pandemic surges will lead to more public health crises. These concerns aren’t unfounded, as TrialSite reported nations such as Russia have plunged back into pandemic-led crisis.